Table 1.

Immunosuppressive regimens known to increase risk of hepatitis B virus reactivation

HBsAg-positive	HBsAg-negative
	Anti-HBc positive
Corticosteroids	Anti-CD20 (e.g., rituximab)
Anti-CD20 (e.g., rituximab)	HSCT
HSCT	Anti-TNF
Anti-TNF	TACE for hepatocellular carcinoma
Anthracyclines	Methotrexate
TACE for hepatocellular carcinoma
Methotrexate
Ustekinumab
Tyrosine kinase inhibitors

HBsAg: Hepatitis B surface antigen; Anti-HBc: Antibody to hepatitis B core antigen; Anti-CD20: Antibody against CD20; Anti-TNF: Antibody against tumor necrosis factor; TACE: Transarterial chemo-embolization; HSCT: Hematopoietic stem cell transplantation.